{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Table 9.4', 'Schedule of Clinical Laboratory Safety Tests, Including Thyroid Panel and', 'Hyperglycemia Monitoring', 'Treatment Period', 'Follow-Up Period', 'Base-', 'W4', 'W12', 'W24', 'W28', 'W36', 'W48', 'W1', 'W3', 'W6', 'W9', 'W15', 'W18', 'W21', 'Analysis Panel', 'line 1', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'Chemistry (excl. glucose)', 'X\u00b2', 'X', 'X', 'Thyroid (FT3, FT4, TSH)', '3', 'Hematology', 'X', 'Glucose 4', 'X', 'HbA1c', 'X5', 'Urinalysis', 'X', 'X', 'Urine pregnancy 6', 'X', 'X', 'FT3=free triiodothyronine; FT4=free thyroxine; HbAlc=glycated hemoglobin; M=Month; TSH=thyroid stimulating hormone;', 'W=Week.', '1.', 'If Day 1 (Baseline) of the extension study occurs on the same day as the final visit of HZNP-TEP-301, assessments do not', 'need to be repeated, and the final assessments from the lead-in study will serve as the Baseline assessments for the extension', 'study.', '2.', 'ALT/AST must be VI 3 X the ULN and serum creatinine must be < 1.5 X the ULN (according to age) at most recent clinic', 'visit for enrollment.', '3.', 'Subjects must be euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism (defined as FT4', 'and FT3 levels < 50% above or below the normal limits) at the most recent clinic visit. Every effort should be made to', 'correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the clinical', 'trial.', '4.', 'Non-diabetic subjects will fast at Weeks 1 and 4 only. Diabetic subjects will fast for each blood glucose evaluation. NOTE:', 'Subjects with severe hyperglycemia that does not abate to mild or moderate intensity with anti-diabetic treatment (dose may', 'be skipped up to 2 times prior to permanently discontinuing study drug, see Section 9.4.6.3.2 for details) will be', 'permanently discontinued from study drug.', '5.', 'HbA1c must be < 9.0% at most recent clinic visit for enrollment. If the HbAlc is elevated and considered clinically', 'significant at any time point after Baseline, it will be repeated approximately every 45 days until it returns to normal or', 'baseline value.', '6.', 'Perform for female subjects of childbearing potential (including those with an onset of menopause <2 years prior to', 'Screening of HZNP-TEP-301, non-therapy-induced amenorrhea for <12 months prior to Screening of HZNP-TEP-301, or', 'not surgically sterile [absence of ovaries and/or uterus]).', 'Instructions for the collection, handling and analysis of clinical laboratory samples will be', 'provided to the site prior to study site initiation.', '9.5.4.7 Immunogenicity Testing', 'Blood samples will be collected in a 5 mL SST collection tube for immunogenicity testing (ADA', 'and possibly Neutralizing Antibodies [NAb]) from all subjects prior to dosing on Day 1, prior to', 'dosing on Weeks 3 and 9, and at Week 24 of the Treatment Period, and Months 9 and 12 (or', 'PW) of the Follow-Up Period. Samples will be collected, processed, and stored at > - -70\u00b0C at the', 'site until shipment to the central laboratory', 'will', 'store the samples at >-70\u00b0C until shipment to', 'for immunogenicity testing. If a subject', 'tests positive for ADA after confirmatory and reactive titer testing, the sample will then be tested', 'for NAb. If the subject tests positive for NAb, he/she will be followed until levels either revert to', \"Baseline or the subject's value decreases or remains stable. Any subject with a positive NAb test\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 93 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', \"at Month 12 (or PW) of the Follow-Up Period will continue to be followed until the subject's\", 'value decreases or remains stable.', 'Instructions for processing, handling, storing, and shipping of immunogenicity samples will be', 'detailed in a laboratory manual that will be provided to each site prior to site initiation.', '9.5.4.8 Data Safety Monitoring Board', 'The study will be monitored by a DSMB, which will advise the Sponsor regarding the', 'continuing safety of study subjects and potential subjects as well as continuing validity and', 'scientific merit of the trial. The details regarding frequency of meetings, members, and the safety', 'review criteria will be outlined in a separate DSMB Charter. ACI Clinical will manage the', 'logistics of the DSMB (Table 6.1).', '9.5.5 Appropriateness of Measurements', 'The study population consists of subjects with TED who participated in the lead-in study', '(HZNP-TEP-301) and were either proptosis non-responders at Week 24 of HZNP-TEP-301 or', 'were proptosis responders at Week 24 but met the criteria for re-treatment due to relapse (see', 'Section 9.3.4) during the Follow-Up Period of HZNP-TEP-301. The study population enrolled in', 'HZNP-TEP-301 was well-defined and consistent with the expected target population for whom', 'teprotumumab will be indicated (adult subjects with moderate-to-severe TED).', 'The measurements used in this study for the primary and secondary endpoints (proptosis, CAS,', 'diplopia and GO-QoL questionnaire) are established endpoints that have been shown to correlate', 'significantly with TED.', '9.5.6 Study Procedures', 'Subjects who provide informed consent and who meet all the entry criteria for participation in', 'this study will be enrolled in the open-label extension study.', '9.5.6.1 Day 1/Baseline', 'The Baseline (Day 1) Visit must occur within 14 days of the final visit of HZNP-TEP-301. If', 'Day 1 of the extension study occurs on the same day as the final visit of HZNP-TEP-301 and an', 'assessment is scheduled for both visits, assessments do not need to be repeated, and the final', 'assessments from the lead-in study will serve as the Baseline assessments for the extension', 'study.', 'Potential study subjects will be informed fully regarding the nature of the study and possible', 'AEs, and will receive a copy of the ICF for review. Potential study subjects must read the ICF', \"and sign the document after the Investigator has answered all questions to the study candidate's\", 'satisfaction. Further procedures can begin only after the ICF has been signed. The original signed', 'ICF will be retained by the Investigator and a copy will be given to the study subject.', 'Study candidates will be evaluated for study entry according to the stated inclusion and exclusion', 'criteria (Section 9.3). The Investigator will evaluate the results of all examinations, including', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 94 of 118']\n\n###\n\n", "completion": "END"}